Skip to main content
. Author manuscript; available in PMC: 2018 Jan 8.
Published in final edited form as: Nature. 2017 May 10;545(7654):305–310. doi: 10.1038/nature22075

Extended Data Figure 5. The Slco1c1(BAC)-CreERT2 (iBrECre) transgene expresses selectively in brain endothelial cells and iBrECre-driven deletion of Krit1 confers CCM formation in neonatal mice.

Extended Data Figure 5

a, R26-LSL-RFP, Cdh5(PAC)-CreERT2;R26-LSL-RFP and Slco1c1(BAC)-CreERT2;R26-LSL-RFP neonates were induced with tamoxifen injection on P1+2 (two total doses). Immunostaining for RFP and PECAM was performed at P10 in the indicated tissues. Results are representative of at least three animals per group and three independent experiments. Scale bars, 100 μm. Note the presence of RFP+ PECAM+ cells in the brain, small intestine, cecum, colon and liver of Cdh5(PAC)-CreERT2;R26-LSL-RFP animals, but only in the brain of Slco1c1(BAC)-CreERT2;R26-LSL-RFP animals. b, Visual (top) and corresponding microCT (bottom) images of brains from susceptible iBrECre;Krit1fl/+ and iBrECre;Krit1fl/fl P10 animals. Arrow indicates CCM lesions in the cerebrum. Scale bars, 1 mm. c, H&E staining of cerebellum (hindbrain) from the indicated animals (left). H&E staining of cerebrum (forebrain) from the indicated animals (middle). KLF4 and PECAM immunostaining from the indicated animals (right). Scale bars, 50 μm. Asterisks denote CCM lesions. N≥5 per group.